News & Views
Collaboration to Investigate Potential Antibody Candidates
May 14 2021
Global immunology company argenx has signed an agreement with FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS) to explore diverse panels of novel antibody candidates within IONTAS’ proprietary mammalian display technology. The agreement includes provision of a dedicated full-time team assigned to the project.
Both companies have highly complementary capabilities for identification of potential next-generation antibody candidates, including argenx’s pipeline of investigational immunology therapies aimed at improving the lives of people living with severe autoimmune diseases and cancer. Through its Immunology Innovation Program, argenx collaborates with leading researchers to translate immunology breakthroughs in disease biology into differentiated therapeutic antibodies.
Dr António Parada, CEO at FairJourney Biologics and IONTAS commented: “We have gained considerable experience in antibody discovery through mammalian display for use in generating therapeutics with specific properties.
“Additionally, we continue to make improvements to the technology that will allow more diverse applications. We look forward to growing our relationship with argenx and applying our deep knowledge and experience to generate a diverse set of antibodies for potential immunological application.”
More information online
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria